Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, October 24, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, October 21, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matt Miksic Maintained (ABT) at Buy with Decreased Target to $114 on, Oct 21st, 2022
Matt Miksic of Barclays, Maintained "Abbott Laboratories" (ABT) at Buy with Decreased Target from $118 to $114 on, Oct 21st, 2022.
Matt has made no other calls on ABT in the last 4 months.
There are 16 other peers that have a rating on ABT. Out of the 16 peers that are also analyzing ABT, 1 agrees with Matt's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Taylor of "Jefferies" Initiated at Hold and Held Target at $110 on, Wednesday, October 12th, 2022
These are the ratings of the 15 analyists that currently disagree with Matt
- Cecilia Furlong of "Morgan Stanley" Maintained at Buy with Decreased Target to $117 on, Thursday, October 20th, 2022
- Joanna Wiensch of "Citigroup" Maintained at Strong Buy with Decreased Target to $114 on, Thursday, October 20th, 2022
- Marie Thibault of "BTIG" Maintained at Strong Buy with Decreased Target to $120 on, Thursday, October 20th, 2022
- Rick Wise of "Stifel" Maintained at Strong Buy with Decreased Target to $110 on, Thursday, October 20th, 2022
- Robbie Marcus of "JP Morgan" Maintained at Buy with Decreased Target to $118 on, Thursday, October 20th, 2022
- Shagun Singh of "RBC Capital" Maintained at Buy with Decreased Target to $126 on, Thursday, October 20th, 2022
- Vijay Kumar of "Evercore ISI Group" Maintained at Buy with Decreased Target to $110 on, Wednesday, October 19th, 2022
- Ryan Zimmerman of "BTIG" Maintained at Strong Buy with Decreased Target to $123 on, Monday, October 17th, 2022
- Larry Biegelsen of "Wells Fargo" Maintained at Buy with Decreased Target to $140 on, Monday, October 10th, 2022
- David Toung of "Argus Research" Maintained at Strong Buy with Decreased Target to $135 on, Thursday, July 28th, 2022
- John Sourbeer of "UBS" Maintained at Strong Buy with Decreased Target to $128 on, Wednesday, July 27th, 2022
- Amit Hazan of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $104 on, Monday, July 25th, 2022
- Joanne Wuensch of "Citigroup" Maintained at Strong Buy with Decreased Target to $123 on, Thursday, July 21st, 2022
- Joshua Jennings of "TD Cowen" Maintained at Buy with Decreased Target to $130 on, Wednesday, July 13th, 2022
- Mike Polark of "Wolfe Research" Initiated at Sell on, Wednesday, July 6th, 2022
